当前位置: X-MOL 学术Mol. Cell. Toxicol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Characteristic molecular signature of pericardial effusion identifies malignant cancer in pericardial disorder patients
Molecular & Cellular Toxicology ( IF 1.7 ) Pub Date : 2020-04-03 , DOI: 10.1007/s13273-020-00076-8
Sang Yean Kim , Jung Woo Eun , Hyung Seok Kim , Hee Doo Yang , Min Jeong Na , Young Min Ahn , Hae Ok Jung , Suk Woo Nam

Background

Pericardial effusion (PE) can develop in patients with virtually any condition that affects the pericardium, including acute pericarditis and a variety of systemic disorders. Thus, definite differentiation of malignant pericardial effusion and rapid diagnosis are known to have therapeutic and prognostic importance.

Objective

The aim of this study was to identify novel molecular markers for the detection of cancer in patients with pericardial disorder.

Results

We performed one-way ANOVA analysis of whole transcriptome scans of 18 PEs from the patients with pericardial disorder including cancer. It resulted in 4385 outlier genes. Hierarchical clustering analysis showed two distinct clusters [cancer patient’s PEs (G1 + G2) vs. non-cancer PEs (G3)] within the dendrogram. To identify cancer-specific molecular signature, Welch’s t test of G1 and G3 was performed and 1639 gene elements were suggested as stringent classifiers between cancer PE and non-cancer PE. Gene set enrichment analysis of PE signature suggested that CD24, SDC1, and ST14 were strong molecular markers for identifying cancer patients among patients with pericardial disorder.

Conclusion

Our results suggest that etiology-specific molecular signatures can discriminate cancer patients within pericardial disorder patients. CD24, SDC1, and ST14 are strong molecular markers for such discrimination.



中文翻译:

心包积液的特征性分子标记可确定心包疾病患者的恶性肿瘤

背景

实际上,患有任何会影响心包的疾病的患者都会出现心包积液,包括急性心包炎和各种系统性疾病。因此,已知恶性心包积液的明确分化和快速诊断具有治疗和预后的重要性。

目的

这项研究的目的是确定新的分子标记,以检测心包疾病患者的癌症。

结果

我们对包括癌症在内的心包疾病患者的18个PE进行了全转录组扫描的单向ANOVA分析。结果产生了4385个离群基因。层次聚类分析显示树状图中有两个不同的聚类[癌症患者的PE(G1 + G2)与非癌症PE(G3)]。为了鉴定癌症特异性分子标记,对G1和G3进行了Welch的t检验,并建议使用1639个基因元件作为癌症PE和非癌症PE之间的严格分类器。PE签名的基因集富集分析表明,CD24,SDC1和ST14是在心包疾病患者中鉴定癌症患者的强分子标记。

结论

我们的结果表明,病因特异性分子标记可以区分心包疾病患者中的癌症患者。CD24,SDC1和ST14是此类区分的强分子标记。

更新日期:2020-04-03
down
wechat
bug